Literature DB >> 25171322

National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines.

Emilie Sbidian1, Pirayeh Eftekahri, Manuelle Viguier, Liliane Laroche, Olivier Chosidow, Pierre Gosselin, Fabienne Trouche, Nathalie Bonnet, Catherine Arfi, Florence Tubach, Hervé Bachelez.   

Abstract

BACKGROUND: Psoriasis is a common chronic immune-mediated disease resulting from interactions of a genetic background with environmental triggering factors such as stress and infection. So far, there is very limited information available about the impact of vaccine stimuli on psoriasis course.
OBJECTIVE: To collect cases of psoriasis flares occurring after vaccination through a national survey.
METHODS: We investigated cases of onset or flare of psoriasis occurring within 3 months following the 2009 monovalent H1N1/seasonal vaccination during the campaign of the 2009-2010 flu seasons in France.
RESULTS: Ten patients, 6 men and 4 women with a median age of 44 years (range 9-88), were reported with a psoriasis of new onset (n = 7) or with a worsening of previously diagnosed psoriasis (n = 3) within a median time period of 8 days following vaccination. Nine of them presented with a mixed guttate/plaque clinical phenotype, and 1 showed 2 successive generalized pustular psoriasis (GPP) flares after 2 different vaccine injections.
CONCLUSION: The short time interval between vaccination and onset of psoriasis flares, the lack of other triggers and the flaring sequence following 2 different vaccines in a GPP patient suggest a possible association between the 2009 monovalent H1N1/seasonal vaccination and psoriasis flaring in the collected cases. Nevertheless, the likely very low incidence of psoriasis following vaccination emphasizes the safe profile and the relevance of vaccination strategies in psoriasis patients, especially in candidates for immunosuppressive treatments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25171322     DOI: 10.1159/000362808

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  13 in total

1.  Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.

Authors:  Patricia Winokur; Hana M El Sahly; Mark J Mulligan; Sharon E Frey; Richard Rupp; Evan J Anderson; Kathryn M Edwards; David I Bernstein; Kenneth Schmader; Lisa A Jackson; Wilbur H Chen; Heather Hill; Abigail Bellamy
Journal:  Vaccine       Date:  2021-01-21       Impact factor: 3.641

2.  RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease.

Authors:  Huiyuan Zhu; Fangzhou Lou; Qianqian Yin; Yuanyuan Gao; Yang Sun; Jing Bai; Zhenyao Xu; Zhaoyuan Liu; Wei Cai; Fang Ke; Lingyun Zhang; Hong Zhou; Hong Wang; Gang Wang; Xiang Chen; Hongxin Zhang; Zhugang Wang; Florent Ginhoux; Chuanjian Lu; Bing Su; Honglin Wang
Journal:  EMBO Mol Med       Date:  2017-05       Impact factor: 12.137

3.  Building a Citizen Pscientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts.

Authors:  Isabelle M Sanchez; Lindsey Shankle; Marilyn T Wan; Ladan Afifi; Jashin J Wu; Frank Doris; Alisha Bridges; Marc Boas; Brian Lafoy; Sarah Truman; Ana-Maria Orbai; Junko Takeshita; Joel M Gelfand; April W Armstrong; Michael P Siegel; Wilson Liao
Journal:  Dermatol Ther (Heidelb)       Date:  2018-06-06

4.  Possible Triggering Effect of Influenza Vaccination on Psoriasis.

Authors:  Ali Tahsin Gunes; Emel Fetil; Sevgi Akarsu; Ozlem Ozbagcivan; Lale Babayeva
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

Review 5.  Risk Factors for the Development of Psoriasis.

Authors:  Koji Kamiya; Megumi Kishimoto; Junichi Sugai; Mayumi Komine; Mamitaro Ohtsuki
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

6.  Psoriasis flare after influenza vaccination in Covid-19 era: A report of four cases from a single center.

Authors:  Pablo Munguía-Calzada; Marta Drake-Monfort; Susana Armesto; Leandra Reguero-Del Cura; Ana Elisabet López-Sundh; Marcos Antonio González-López
Journal:  Dermatol Ther       Date:  2020-12-22       Impact factor: 3.858

7.  How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.

Authors:  Francesca Ferretti; Rosanna Cannatelli; Maurizio Benucci; Stefania Carmagnola; Emilio Clementi; Piergiorgio Danelli; Dario Dilillo; Paolo Fiorina; Massimo Galli; Maurizio Gallieni; Giovanni Genovese; Valeria Giorgi; Alessandro Invernizzi; Giovanni Maconi; Jeanette A Maier; Angelo V Marzano; Paola S Morpurgo; Manuela Nebuloni; Dejan Radovanovic; Agostino Riva; Giuliano Rizzardini; Gianmarco Sabiu; Pierachille Santus; Giovanni Staurenghi; Gianvincenzo Zuccotti; Pier Carlo Sarzi-Puttini; Sandro Ardizzone
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

Review 8.  Biologics for Psoriasis during the COVID-19 Pandemic.

Authors:  Koji Kamiya; Mayumi Komine; Mamitaro Ohtsuki
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

Review 9.  Psoriasis: To Vaccinate or Not to Vaccinate?

Authors:  Christian Summa; Poonam Patel; Marc M Kesselman; Michelle Demory Beckler
Journal:  Cureus       Date:  2021-06-23

10.  Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases.

Authors:  Prateek Nagrani; Rashmi Jindal; Dikshita Goyal
Journal:  Dermatol Ther       Date:  2021-08-10       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.